Condition: Short Bowel Syndrome · Sponsor: Zealand Pharma
The purpose of the present Phase 3 trial is to confirm the efficacy and safety of glepaglutide 10 mg twice weekly in a patient population with SBS-IF and generate additional long-term safety data. Glepaglutide is the International Nonproprietary Name and United States Adopted Name (USAN) for ZP1848.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Washington University Center for Advanced Medicine | St Louis, Missouri, United States | Recruiting |
| Lied Transplant Center at Nebraska Medical Center | Omaha, Nebraska, United States | Recruiting |
| New York Presbyterian Hospital-Columbia University Medical Center | New York, New York, United States | Not Yet Recruiting |
| Vanderbilt University Medical Center | Nashville, Tennessee, United States | Recruiting |
| Universitätsklinikum AKH Wien | Vienna, State of Vienna, Austria | Recruiting |
| Rigshospitalet-Blegdamsvej 9 | Copenhagen, Denmark | Recruiting |
| AP-HP - Hôpital Beaujon | Clichy, France | Recruiting |
| Universitätsmedizin Rostock | Rostock, Mecklenburg-Vorpommern, Germany | Recruiting |
| Eugastro Klinische Studien GmbH | Leipzig, Saxony, Germany | Recruiting |
| Charité - Universitätsmedizin Berlin | Berlin, Germany | Recruiting |
| Universitätsklinikum Bonn | Bonn, Germany | Recruiting |
| Asklepios Klinik St. Georg | Hamburg, Germany | Recruiting |
+ 11 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07197944